For noninfectious diarrhea in adults living with HIV who are on ART

An antisecretory antidiarrheal that:

  • Works by normalizing fluid and electrolyte balance in the GI tract to provide symptomatic relief of diarrhea
  • Is not an opioid and does not affect GI motility

Minimally absorbed, well-tolerated, and demonstrated to have:

  • No clinically relevant drug-drug interactions
  • No effect on viral load or CD4 counts
  • Adverse events comparable to those with placebo

NOVEL ANTIDIARRHEAL MECHANISM

Mytesi regulates two chloride ion channels in the intestinal lumen (CFTR and CaCC), which normalizes fluid and electrolyte balance in the GI tract—with very low risk of constipation

For noninfectious diarrhea in adults living with HIV who are on ART

Mytesi—The only FDA-approved treatment for symptomatic relief of diarrhea in people with HIV

baseline

Mytesi 125-mg twice daily was approved based on a randomized trial in HIV+ patients who are on stable ART and have a history of diarrhea for ≥1 month1

Results over time with Mytesi2†

Week 4 on Mytesi 125-mg BID

61% of patients had at least a
50% decrease in watery stools

Week 20 on Mytesi 125-mg BID

83% of patients had at least a
50% decrease in watery stools

Daily diary data were evaluated in a supplemental analysis from all patients treated with Mytesi 125-mg BID in the ADVENT trial for up to 24 weeks. The average reduction in watery stools from baseline was determined by week.

Know when your patients have had ENOUGH.

Sometimes it's about asking the right question...

Ask every hiv patient about diarrhea

NapoCares™️ Patient Support

Connect your eligible adult patients living with HIV to resources that help them access Mytesi.

To enroll your eligible patients in the Mytesi Copay Savings Card program call 1-888-527-NAPO (6276)

Patient must have commercial insurance for eligibility. Subject to change or cancellation at any time and without notice.

copay card
  1. Gehrig M, Clay P, Perry R, et al. Actual versus perceived use of pharmacokinetic (primarily absorption) influential OTC agents and ART tolerability in a nationwide matched cohort of HIV patients and their healthcare providers. Poster abstract presented at: ID Week 2016; October 26-30, 2016; New Orleans, LA.
  2. MacArthur RD, Clay P, Blick G, et al. Long-Term Crofelemer Provides Clinically Relevant Reductions in HIV-Related Diarrhea. Poster presented at: 9th IAS Conference on HIV Science (IAS 2017); 2017 July 23-26; Paris, France.